Last updated: September 9, 2026
Acamprosate calcium is a mature, multisource alcohol-use-disorder medicine with limited remaining branded economics. U.S. commercial value shifted from Forest Laboratories’ Campral franchise to low-priced generic supply after FDA approval of generic delayed-release tablets. The product has no biosimilar exposure, limited formulation differentiation, and low barriers to generic manufacture. Its market outlook depends more on alcohol-use-disorder diagnosis, treatment access, payer coverage, and adherence than on patent protection.
What is acamprosate calcium used for?
Acamprosate calcium is an oral prescription medicine used to maintain abstinence in adults with alcohol dependence who are already abstinent when treatment begins. It is not an acute alcohol-withdrawal treatment and does not prevent withdrawal symptoms.
The U.S. product is a 333 mg delayed-release tablet administered as two tablets three times daily, for a total daily dose of 1,998 mg. Patients with moderate renal impairment receive a reduced dose, while the drug is contraindicated in severe renal impairment. Acamprosate is eliminated primarily through the kidneys and has limited hepatic metabolism, which differentiates it from some competing alcohol-use-disorder therapies (FDA, 2023).
| Attribute |
Acamprosate calcium |
| U.S. brand |
Campral |
| Active ingredient |
Acamprosate calcium |
| Dosage form |
Delayed-release tablet |
| Strength |
333 mg |
| Standard adult dose |
666 mg three times daily |
| FDA indication |
Maintenance of abstinence from alcohol |
| U.S. approval |
2004 |
| Controlled-substance status |
Not a controlled substance |
| Primary elimination |
Renal |
| Major safety constraint |
Severe renal impairment |
| Current market structure |
Generic, multisource |
Acamprosate is generally used after detoxification and initial abstinence. Its commercial uptake is constrained by the requirement for three-times-daily dosing, the need for baseline abstinence, and competition from therapies with simpler administration.
How large is the acamprosate calcium market?
The U.S. market is a low-value generic prescription market rather than a branded specialty-pharmaceutical market. Public companies generally do not disclose acamprosate revenue separately, preventing a reliable standalone estimate from audited filings.
Market demand is supported by the large population affected by alcohol-use disorder. The National Survey on Drug Use and Health estimated that millions of U.S. adults have alcohol-use disorder, but only a minority receive medication treatment. That treatment gap creates clinical volume potential without translating directly into high product revenue because acamprosate is inexpensive and faces generic competition (SAMHSA, 2023).
Principal demand drivers
- Growth in screening and diagnosis of alcohol-use disorder.
- Expansion of behavioral-health and addiction-treatment services.
- Greater use of medication-assisted treatment in outpatient settings.
- Increased recognition of alcohol-use disorder in primary care.
- Generic affordability and broad pharmacy availability.
Principal demand constraints
- Three-times-daily dosing.
- Requirement that treatment begin after abstinence.
- Renal dosing restrictions.
- Competition from once-daily oral naltrexone and monthly injectable naltrexone.
- Low medication adherence in alcohol-use-disorder populations.
- Limited provider familiarity compared with naltrexone.
- Reimbursement and treatment-access limitations.
The market has clinical relevance but weak pricing power. Volume can increase while supplier revenue remains flat or declines because generic price competition offsets prescription growth.
What is the financial trajectory for acamprosate calcium?
Acamprosate’s financial trajectory has four stages:
| Period |
Commercial condition |
Financial effect |
| 2004 to early generic era |
Campral launched in the U.S. |
Branded revenue opportunity |
| Pre-generic maturity |
Established treatment option with limited differentiation |
Moderate but niche revenue |
| Generic entry |
ANDA-based competition begins |
Rapid price and share erosion |
| Current mature-generic period |
Multiple suppliers and low unit pricing |
Low revenue per prescription and limited margin |
Forest Laboratories marketed Campral in the United States after FDA approval. The company’s public reporting did not establish acamprosate as a major revenue contributor relative to products such as Lexapro and Namenda. After generic competition, acamprosate lost the commercial characteristics associated with a protected branded product.
There is no dependable basis for assigning a current global market valuation from public filings alone. The relevant commercial metrics are prescription volume, average generic selling price, wholesaler concentration, pharmacy-channel access, and supplier manufacturing cost.
Revenue exposure for manufacturers
For generic manufacturers, acamprosate is likely a portfolio product rather than a strategic growth asset. Revenue exposure has the following characteristics:
- Low average selling price.
- Limited differentiation between suppliers.
- Potentially stable prescription demand.
- High sensitivity to wholesaler and pharmacy purchasing contracts.
- Margin pressure when additional ANDA holders enter.
- Limited ability to offset price declines through premium branding.
For pharmacies and distributors, the product can generate routine prescription volume but generally does not create material specialty-pharmacy economics. For branded pharmaceutical companies, the product does not offer an attractive relaunch profile unless paired with a differentiated adherence system, digital support program, or new indication.
What patents protect acamprosate calcium?
Acamprosate is a small molecule with an aged patent estate. The original U.S. product protection has expired or is no longer commercially meaningful, and the current product is sold through generic ANDA pathways.
The key protection historically related to the active ingredient and its use in alcohol dependence. The present competitive question is not whether a strong compound patent remains but whether any enforceable, listed formulation or method-of-use patent could delay a specific generic product.
| Protection category |
Current commercial assessment |
| Compound patent |
Expired or commercially exhausted |
| Basic alcohol-dependence use |
Expired or commercially exhausted |
| Delayed-release formulation |
No meaningful branded barrier identified in the current mature-generic market |
| Manufacturing process |
Potentially protectable at the supplier level, but not a broad market barrier |
| Pediatric exclusivity |
Not a current commercial driver |
| Orphan exclusivity |
Not applicable to the marketed indication |
| Biosimilar protection |
Not applicable because acamprosate is a small molecule |
What formulations are protected by acamprosate patents?
The marketed U.S. product is a delayed-release tablet. Any formulation value lies in manufacturing execution, tablet stability, dissolution performance, and regulatory compliance rather than in a commercially durable branded patent moat.
A new acamprosate formulation could potentially target twice-daily or once-daily administration, improved tolerability, or adherence support. Such a product would require clinical, regulatory, and reimbursement investment. A reformulation would not automatically receive strong market protection unless it produced meaningful clinical differentiation and obtained enforceable intellectual-property rights.
What manufacturing barriers affect acamprosate?
Manufacturing barriers are moderate at the operational level and low at the market level. Suppliers must control:
- Active pharmaceutical ingredient consistency.
- Calcium salt formation.
- Delayed-release coating performance.
- Dissolution specifications.
- Tablet size and patient acceptability.
- Stability through the labeled shelf life.
- FDA current good manufacturing practice compliance.
These requirements can exclude poorly prepared entrants, but they do not prevent capable generic manufacturers from competing.
When did acamprosate lose exclusivity?
Campral received FDA approval in 2004. U.S. generic competition emerged in the following decade, and acamprosate is now treated as an established generic product. The practical loss of exclusivity occurred when ANDA-approved competitors entered and pharmacies gained access to interchangeable or substitutable products.
A precise commercial exclusivity date should be distinguished from patent expiration. FDA marketing exclusivity, patent term, pediatric exclusivity, and the date of first commercial generic sale are separate events. FDA’s Orange Book and Drugs@FDA records are the controlling sources for product-specific listing and approval information (FDA, 2024a; FDA, 2024b).
What is the Orange Book status of acamprosate calcium?
The Orange Book identifies Campral and approved generic acamprosate calcium delayed-release tablets through FDA product records. The product is an immediate-substitution generic market rather than a current branded-patent market.
The principal regulatory status is:
- NDA originator: Campral.
- Generic pathway: ANDA approvals.
- Dosage form: delayed-release tablet.
- Therapeutic equivalence: evaluated through FDA’s generic-drug framework.
- Listed patent risk: no active branded patent barrier appears to support a current broad exclusivity position.
- Regulatory category: prescription drug, not a biologic.
Orange Book status can change when FDA updates patent listings, ANDA approvals, therapeutic-equivalence codes, or marketing-status records. Commercial diligence should use the current FDA database for product-level confirmation.
Which companies are challenging acamprosate calcium?
Generic competition is primarily an ANDA market rather than a litigation-led challenge. Publicly identified generic suppliers have included large and mid-sized manufacturers that market acamprosate calcium delayed-release tablets under their own labels or through distribution partners. FDA databases, DailyMed, and current wholesaler listings identify the active supplier set.
The most important competitive distinction is not the identity of a single challenger. It is the number of approved suppliers and the extent to which pharmacies source the product through low-cost contracts.
Are there Paragraph IV challenges?
Paragraph IV litigation was relevant during the transition from Campral to generic competition because an ANDA applicant could challenge listed patents before expiration. The current commercial market does not depend on an active Paragraph IV exclusivity contest. Acamprosate is already a mature generic product with multiple suppliers.
No current high-value Paragraph IV dispute is a central market driver for the product based on publicly available FDA and court information through mid-2024.
What patent litigation affects acamprosate calcium?
Acamprosate has no known current litigation profile comparable to major branded drugs with active compound, formulation, or method-of-use patents. The main historical legal issue was the transition from Campral’s branded position to ANDA-based generic supply.
The litigation risk for a prospective entrant is more likely to involve:
- FDA approval timing.
- Bioequivalence or dissolution deficiencies.
- Manufacturing observations.
- Product liability.
- Labeling or promotional compliance.
- Contract disputes with distributors.
A generic manufacturer is unlikely to face a durable market-blocking patent dispute unless a new formulation or delivery system is introduced.
How does acamprosate compare with competing alcohol-use-disorder drugs?
| Drug |
Administration |
Key commercial advantage |
Key limitation |
Patent exposure |
| Acamprosate |
Three times daily |
Generic cost and renal elimination |
Adherence burden and abstinence requirement |
Mature generic |
| Oral naltrexone |
Once daily |
Simple dosing and broad clinical familiarity |
Hepatic and opioid-related restrictions |
Mature generic |
| Injectable naltrexone |
Monthly injection |
Improved dosing persistence for selected patients |
Higher acquisition cost and administration requirements |
Branded and generic competition varies by market |
| Disulfiram |
Usually once daily |
Long-established deterrent mechanism |
Adherence and safety limitations |
Mature generic |
| Nalmefene |
Market-dependent |
Used in some countries for reduction in drinking |
Limited U.S. commercial role |
Geography-dependent |
Acamprosate’s strongest commercial position is low cost and suitability for patients who are abstinent and have clinical reasons to avoid hepatic metabolism. Its weakest position is adherence. Naltrexone often has greater prescribing familiarity, while injectable naltrexone can command higher revenue per treated patient despite administration and reimbursement barriers.
What is the FDA regulatory status of acamprosate?
FDA approved Campral in 2004 for maintenance of abstinence from alcohol in adults with alcohol dependence who are abstinent at treatment initiation. The FDA label states that acamprosate does not treat acute alcohol withdrawal and does not eliminate or reduce withdrawal symptoms (FDA, 2023).
The regulatory profile is stable:
- No controlled-substance scheduling.
- No biologic-license or biosimilar pathway.
- Generic entry through ANDAs.
- No requirement for a risk evaluation and mitigation strategy identified in the current label.
- Renal function is central to prescribing and labeling.
- Delayed-release formulation is the established U.S. dosage form.
Is there biosimilar risk for acamprosate calcium?
There is no biosimilar risk because acamprosate calcium is a chemically synthesized small molecule, not a biologic. Competition occurs through the Hatch-Waxman generic framework rather than the Biologics Price Competition and Innovation Act.
This distinction matters commercially. The relevant risks are ANDA approvals, therapeutic-equivalence ratings, price competition, supply interruptions, and manufacturing compliance. Biosimilar interchangeability, biologic reference-product exclusivity, and biologic manufacturing complexity do not apply.
Are there licensing deals for acamprosate calcium?
The historical commercialization of Campral involved rights associated with Forest Laboratories and the European development and commercialization network around the product. The commercial significance of those arrangements diminished after generic entry.
No major current licensing transaction is a central value driver for acamprosate calcium. A future deal would be more likely to concern:
- A reformulated extended-release product.
- A digital adherence platform.
- Combination therapy.
- Regional distribution rights.
- An alcohol-use-disorder treatment franchise.
A conventional license for generic acamprosate alone would have limited strategic value unless it included manufacturing scale, preferred payer access, or a differentiated delivery technology.
What generic launch scenarios exist for acamprosate?
Base case
Multiple suppliers maintain supply, prices remain low, and prescription volume tracks the broader alcohol-use-disorder treatment market. Manufacturer revenue remains modest and fragmented.
Upside case
More patients receive medication treatment through primary care and addiction clinics. Prescription volume increases, but generic competition captures much of the incremental value.
Downside case
A supplier exits, manufacturing problems reduce availability, or prescribers shift further toward naltrexone and long-acting therapies. Volume and revenue decline, with temporary price increases possible during shortages.
Differentiated-product case
A company develops a less frequent dosing formulation or adherence-focused product. Commercial success would depend on clinical evidence, FDA approval, reimbursement, and evidence that improved adherence offsets higher pricing.
How strong is the acamprosate patent estate?
The patent estate is weak for a conventional generic-market assessment. Acamprosate has:
- No meaningful active compound exclusivity.
- No biosimilar protection.
- Limited formulation differentiation.
- Low litigation exposure.
- Minimal pricing power.
- A mature generic supply base.
Its clinical utility remains established, but clinical utility does not create market exclusivity. The strongest commercial opportunity lies in improving delivery, adherence, and treatment integration rather than defending the existing tablet through legacy patents.
Key Takeaways
- Acamprosate calcium is a mature generic treatment for maintaining alcohol abstinence.
- Campral’s branded opportunity ended with the arrival of ANDA-approved competition.
- The current market is driven by prescription volume, generic pricing, pharmacy access, and treatment adoption.
- Three-times-daily dosing and the need for preexisting abstinence limit use.
- Acamprosate has no biosimilar exposure because it is a small molecule.
- The existing patent estate does not provide a meaningful market barrier.
- No current major Paragraph IV or patent-litigation event appears to control the market.
- Financial upside is limited for an undifferentiated generic but could emerge from improved dosing or adherence technology.
- The principal competitors are naltrexone, injectable naltrexone, and disulfiram.
- Public filings do not provide a reliable standalone current revenue figure for acamprosate.
FAQs About Acamprosate Calcium Market and Patent Risk
Is acamprosate calcium still under patent?
The marketed acamprosate calcium product is in the mature generic phase. Original branded protections are expired or commercially exhausted, and no broad active patent barrier is central to current U.S. competition.
Is acamprosate calcium a profitable generic drug?
It can generate portfolio revenue, but low pricing, multiple suppliers, and limited differentiation generally constrain profitability. Economics depend on manufacturing cost, contract access, and supplier concentration.
Can acamprosate calcium be substituted with naltrexone?
The drugs are alternatives rather than automatic substitutes. Clinical selection depends on abstinence status, renal and hepatic function, opioid use, adherence, and prescriber judgment.
Does acamprosate calcium require FDA approval for each manufacturer?
Yes. Each manufacturer marketing the product in the United States generally requires an FDA-approved NDA or ANDA, with generic applicants demonstrating pharmaceutical equivalence and bioequivalence under the applicable FDA framework.
Could a once-daily acamprosate product obtain new exclusivity?
A new dosage form could receive patent protection and potentially regulatory exclusivity if it satisfies applicable FDA requirements. Commercial success would require evidence of meaningful adherence or clinical benefit, not merely a different dosing schedule.
References
Food and Drug Administration. (2023). Campral (acamprosate calcium) delayed-release tablets: Prescribing information. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services. https://www.accessdata.fda.gov/scripts/cder/daf/
Substance Abuse and Mental Health Services Administration. (2023). 2022 National Survey on Drug Use and Health: Alcohol use disorder. U.S. Department of Health and Human Services. https://www.samhsa.gov/data/ <|endoftext|>
